Yahoo Web Search

  1. Yahoo Finance Results

  2. ..., March 27, 2017 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced that TRC694 preclinical data will be presented at the upcoming American Association for Cancer Research (AACR) annual meeting to be held April 1-5, 2017, in ...

  3. (ALS) Huntington disease Parkinson Disease hESC Derivatives Showing Way Forward for Eye-related Disorders Age-related Macular Degeneration (AMD) Stargardt Disease Myopic Macular ...

  4. Second Sight is currently underway in a trial to test the safety and utility of the Argus II in individuals with Dry Age-Related Macular Degeneration. Second Sight is also developing ...

  5. Opthea sought advice from the MHRA and MPA based on their extensive ophthalmology experience including assessments of marketing authorisation applications for approved anti-VEGF-A therapies.

  6. IDx and IBM Watson Health Forge Alliance for Eye Health

    PR Newswire via Yahoo FinanceMar 16 13:00 PM

    The alliance aims to help primary care providers, hospitals, health systems, and integrated delivery networks deliver value-based care to patients with diabetic retinopathy and other serious ...

  7. We are also planning to make repackaged Avastin for wet age-related macular degeneration (Wet AMD) and diabetic macular edema (DME), and new mydriatics and anesthetics for ...

  8. Opthea requested the meeting which was held on 8 March (US) with the FDA Division of Transplant and Ophthalmology Products, within the Center for Drug...

  9. The clinical development pipeline for 2017 includes therapeutic candidates for advanced lymphoid malignancies, acute myeloid leukemia, pediatric brain tumors, solid tumors, oral mucositis, type ...

  10. “What I find is, people who are older, in their 70s, who have macular degeneration and could benefit from this, don’t,” Joe says. “I don’t know why. To me, it’s so intuitive and ...

  11. Cramer's 10 best S&P performers since the Great Recession

    CNBC via Yahoo FinanceMar 09 23:16 PM

    No. 3 Regeneron (REGN): This biotech company created a drug called Eylea to treat age-related macular degeneration with a once-a-month injection in the eye that was much better ...

  1. Ads
    related to macular degeneration